Papers - ANDO Yuichi
-
A Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Reviewed
Yuichi Ando, Megumi Inada-inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi.
Cancer Sci Vol. 105 ( 3 ) page： 347-53 2014.1
-
Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Reviewed
Cancer Sci Vol. 101 page： 2601-5 2010
-
UGT1A1*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Invited Reviewed
Yuichi Ando, et al.
Curr Opin Mol Ther Vol. 9 page： 258-262 2007
-
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Reviewed
Yuichi Ando, et al.
Cancer Res Vol. 60 page： 6921-6926 2000